此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours

2021年12月22日 更新者:Lidds AB

A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours

This is a multicentre, open-label, first in man, study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumours. The study includes a dose escalation part and a dose expansion part.

研究概览

地位

终止

条件

干预/治疗

研究类型

介入性

注册 (实际的)

6

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Copenhagen、丹麦
        • Herlev Hospital
      • Stockholm、瑞典
        • Karolinska University Hospital
      • Kaunas、立陶宛
        • Lithuanian University of Health Sciences
      • Vilnius、立陶宛
        • National Cancer Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Signed written informed consent granted before undertaking any study-specific procedures;
  2. Male or female patient ≥18 years of age on the day of consenting to the study;
  3. Histologically or cytologically confirmed diagnosis of solid cancer;
  4. At least 1 advanced solid, palpable, cutaneous or subcutaneous tumour lesion with following characteristics:

    • a cutaneous lesion with of thickness ≥4 mm and diameter ≥25 mm at the longest axis, or
    • a subcutaneous lesion of diameter ≥20 mm at the longest and the shortest axis;
  5. Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0-2;
  6. Patient from one the following categories:

    • Patient for whom no standard therapy exists, or standard therapy is contraindicated, or
    • Patient who is scheduled for other anti-cancer treatment (e.g. radiotherapy, immunological treatment, surgery) which will start after completion of at least one treatment cycle of NZ-DTX, i.e after the end-of-study (EOS) visit.

Exclusion Criteria:

  1. Known hypersensitivity to any of the excipients in the NZ-DTX Depot formulation (docetaxel, calcium sulphate, sodium carboxymethylcellulose);
  2. Life expectancy <3 months;
  3. Bleeding deficiencies or ongoing anticoagulant therapy that would put the patient at increased risk of clinically significant bleeding, in the judgement of the Investigator. If the patient has an international normalised ratio (INR) below 1.2 the Investigator may judge if interruption of anticoagulant therapy is warranted;
  4. Any of the following abnormal laboratory values at screening;

    • Bone marrow function:

      • Absolute neutrophil count (ANC) <1.5 x 109/l;
      • Platelet count <100 x 109/l;
      • Haemoglobin <9.0 mg/dl.
    • Coagulation:

      - International Normalized Ratio (INR) >1.2.

    • Hepatic, renal, and biochemistry parameters:

      • Aspartate transaminase (AST) or alanine transaminase (ALT) >2.5 x upper limit of normal (ULN) (>5 x ULN if liver metastases present)*;
      • Alkaline phosphatase (ALP) >2.5 x ULN;
      • Total bilirubin >1.5 x ULN;
      • Estimated glomerular filtration rate (eGFR) <40 ml/min/1.73 m² using the Modified Cockcroft & Gault formula.

        • For patients with liver impairment who have serum transaminase levels (ALT and/or AST) greater than 1.5 times x ULN - the doses will be restricted to max. 75mg/m2. In the event this is not possible the patient will not be included.
  5. Severe fluid retention, e.g. pulmonary oedema, pleural effusion, pericardial effusion or ascites;
  6. Clinically significant heart disease (i.e. heart failure or myocardial infarction within 6 months of screening, instable angina pectoris);
  7. History of thromboembolic or cerebrovascular events within 6 months of screening;
  8. Major surgery within 2 weeks of screening, or patient not recovered from major surgery;
  9. Known untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of screening;
  10. Not recovered from Grade 2 or higher adverse events (AEs) due to previous treatments, excepting alopecia;
  11. Concurrent participation in another investigational study;
  12. Last investigational drug administration in a prior investigational study within 14 days of study treatment initiation or <5 times the half-life of the investigational drug, whichever is longer;
  13. Last administration of other anti-neoplastic drug within 14 days of study treatment initiation;
  14. Radiotherapy of lesion to be injected within 4 weeks of first treatment with NZ-DTX Depot, or irradiated lesion to be injected without signs of disease progression since irradiation;
  15. For men and women of childbearing potential: Unwillingness to follow contraception requirements;
  16. Female patients with planned or current pregnancy and/or currently breastfeeding;
  17. Any other severe, acute or chronical medical or psychiatric condition or laboratory abnormality that, in the judgement of the Investigator, would make the patient inappropriate for study participation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:NZ-DTX Depot
Docetaxel in NanoZolid formulation, for intratumoural injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.
大体时间:5 weeks
The MTD will be determined by incidence of DLTs
5 weeks
The recommended Phase 2 dose (RP2D) of NZ-DTX Depot given as an intra-tumoural injection in a solid, palpable cutaneous or subcutaneous tumour lesion.
大体时间:5 weeks
The RP2D will be determined by frequency and severity of adverse events
5 weeks

次要结果测量

结果测量
措施说明
大体时间
Frequency and severity of treatment-emergent adverse events [safety and tolerability] following an intratumoural injection of NZ-DTX Depot
大体时间:5 weeks
Frequency and severity of treatment-emergent adverse events
5 weeks
Plasma concentration of docetaxel, following an intratumoural injection of NZ-DTX Depot
大体时间:5 weeks
Plasma concentration of docetaxel
5 weeks
Anti-tumour effect following an intratumoural injection of NZ-DTX Depot
大体时间:5 weeks
Tumour response by RECIST
5 weeks

其他结果措施

结果测量
措施说明
大体时间
Presence of immune biomarkers in plasma, following an intratumoural injection of NZ-DTX Depot
大体时间:9 weeks
Analysis of cytokines in plasma
9 weeks
Presence of immune biomarkers in tissue, following an intratumoural injection of NZ-DTX Depot
大体时间:9 weeks
Immunohistochemistry analysis [PD-L1] in tissue
9 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Charlotta Gauffin, PhD、Lidds AB

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年2月28日

初级完成 (实际的)

2021年10月7日

研究完成 (实际的)

2021年10月7日

研究注册日期

首次提交

2021年3月18日

首先提交符合 QC 标准的

2021年3月19日

首次发布 (实际的)

2021年3月22日

研究记录更新

最后更新发布 (实际的)

2021年12月30日

上次提交的符合 QC 标准的更新

2021年12月22日

最后验证

2021年12月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅